Transplantační medicína

A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Explora cómo belumosudil actúa en el sistema inmunológico: un mecanismo de acción que, mediante la inhibición selectiva de ROCK2, equilibra las células inflamatorias y reguladoras para controlar respuestas autoinmunes. Una animación clara y precisa que explica su acción terapéutica paso a paso.

Cuando los agentes sistémicos fallan, Rezurock ofrece una opción de tratamiento innovadora que reduce la inflamación y la fibrosis. Respaldado por el estudio clínico, ROCKstar, mejora la calidad de vida del paciente.

Aplicaciones Preventivas de los Lisiados Bacterianos

Har du spørgsmål til Fabry sygdom?

At the BR1DGE symposium at EASD 2024, leading experts shared new insights on early-stage (Stage 1 and 2) autoimmune type 1 diabetes (T1D), emphasizing the importance of screening for islet antibodies (IAbs) together with monitoring and education. Early type 1 diabetes identification can help to prepare people for a life with T1D.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.